NCT01598103 - Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

Neurogenic Urinary BladderNeurogenic Bladder DisorderNeurogenic Dysfunction of the Urinary BladderNeurogenic Bladder, UninhibitedNeurogenic Bladder, Spastic

Interventions

DRUG

SAF312

One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)

DRUG

Placebo to SAF312

One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)

Trial Locations (3)

8008

Novartis Investigative Site, Zurich

D-82419

Novartis Investigative Site, Murnau am Staffelsee

Unknown

Novartis Investigative Site, Nijmegen